FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
This article was originally published in PharmAsia News
Executive Summary
FDA has accepted Otsuka's new drug application for the investigational V2-vasopressin receptor antagonist tolvaptan, which could enter an increasingly crowded market
You may also be interested in...
Otsuka’s Novel Samska Gets U.S. Advisory Committee Review
U.S. FDA's Cardiovascular and Renal Drugs Advisory Committee will meet June 25 to evaluate Otsuka Pharmaceutical's hyponatremia drug Samska (tolvaptan) for approval in patients with hypervolemic and euvolemic hyponatremia.
Astellas' Vaprisol Receives Second Indication
FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).